Catalent makes new appointment
![](/46/pdcnewsitem/03/76/08/Catalent.png)
Wetteny Joseph chosen to lead the company’s Clinical Supply Services Business.
Catalent Pharma Solutions has appointed Wetteny Joseph as its new President, Clinical Supply Services.
Mr Joseph first joined Catalent in 2008 as Corporate Controller, and in 2012, was charged with leading the finance function for the company’s Modified Release Technologies business unit. In 2013, Mr Joseph was promoted to Vice President of Finance for Catalent’s Development and Clinical Services division, which included the Clinical Supply Services business unit.
“I have the utmost confidence in Wetteny’s ability to lead our Clinical Supply Services business, in which we have invested significantly over the last few years,” commented Catalent CEO and President, John Chiminski. He added: “Wetteny’s expert contribution to the 2012 acquisition of Aptuit, and more recent major capacity and capability upgrades, have strengthened our global reach in Asia Pacific, increased our overall capacity, and broadened our service offering in the clinical services market.”
Before joining Catalent, Mr Joseph held senior financial positions at HD Supply, including CFO of a $1.2 billion business unit. He also served as Corporate Controller at Hughes Supply, a Fortune 500 company. In his early career, Mr Joseph spent 6 years at PricewaterhouseCoopers as an auditor, and as a strategic financial advisor across a variety of industries.
Mr Joseph earned both his master’s and bachelor’s degrees in accounting from Florida Atlantic University.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance